News Releases News Releases Year None20242023202220212020201920182016 December 10, 2024 NextCure Announces Acceptance of IND Application for LNCB74 November 26, 2024 NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference November 19, 2024 Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta November 7, 2024 NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results November 5, 2024 NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting October 4, 2024 NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting September 16, 2024 NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 August 1, 2024 NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results June 20, 2024 NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference May 30, 2024 NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18 Tools
News Releases Year None20242023202220212020201920182016 December 10, 2024 NextCure Announces Acceptance of IND Application for LNCB74 November 26, 2024 NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference November 19, 2024 Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta November 7, 2024 NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results November 5, 2024 NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting October 4, 2024 NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting September 16, 2024 NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 August 1, 2024 NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results June 20, 2024 NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference May 30, 2024 NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 18